

# Anders Wahlin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/670737/publications.pdf>

Version: 2024-02-01

125  
papers

4,728  
citations

126907

33  
h-index

106344

65  
g-index

125  
all docs

125  
docs citations

125  
times ranked

5118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor. <i>British Journal of Haematology</i> , 2020, 188, 187-191.	2.5	7
2	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1770-1778.	2.0	25
3	Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 35-42.	1.4	25
4	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	1.9	3
5	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. <i>Blood</i> , 2016, 128, 3246-3246.	1.4	0
6	Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. <i>American Journal of Hematology</i> , 2015, 90, 208-214.	4.1	202
7	Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2015, 5, 7920.	3.3	12
8	Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2015, 94, 419-423.	2.2	14
9	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4535-4535.	1.6	0
10	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database. <i>Journal of Clinical Oncology</i> , 2015, 33, e15559-e15559.	1.6	0
11	Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014. <i>Blood</i> , 2015, 126, 4888-4888.	1.4	0
12	Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. <i>Blood Cancer Journal</i> , 2014, 4, e188-e188.	6.2	48
13	Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 281-281.	1.4	0
14	Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013. <i>Blood</i> , 2014, 124, 2269-2269.	1.4	0
15	High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. <i>Medical Oncology</i> , 2013, 30, 762.	2.5	2
16	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1670-1676.	2.0	26
17	Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23. <i>Blood</i> , 2013, 121, 4791-4799.	1.4	88
18	Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. <i>Blood</i> , 2013, 122, 2162-2166.	1.4	127

#	ARTICLE	IF	CITATIONS
19	Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia. <i>Diagnostic Molecular Pathology</i> , 2012, 21, 225-233.	2.1	21
20	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	3.5	110
21	Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study. <i>Leukemia and Lymphoma</i> , 2012, 53, 503-505.	1.3	0
22	Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1699-1705.	1.3	13
23	Poor Outcome in Secondary Acute Myeloid Leukemia (AML): A First Report From the Population-Based Swedish Acute Leukemia Registry. <i>Blood</i> , 2012, 120, 130-130.	1.4	9
24	Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden. <i>Leukemia and Lymphoma</i> , 2011, 52, 69-71.	1.3	6
25	Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts. <i>Medical Oncology</i> , 2011, 28, 552-558.	2.5	13
26	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	1.4	74
27	Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. <i>Leukemia</i> , 2011, 25, 1128-1134.	7.2	276
28	Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study. <i>American Journal of Hematology</i> , 2011, 86, 709-710.	4.1	9
29	Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia. <i>Cancer</i> , 2011, 117, 4238-4246.	4.1	51
30	Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. <i>Bone Marrow Transplantation</i> , 2011, 46, 870-875.	2.4	18
31	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	1.4	89
32	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	1.4	204
33	Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation. <i>Acta Haematologica</i> , 2010, 124, 19-22.	1.4	5
34	Copy Number Variations In Acute Leukemia with Cytogenetically Detected 11q23 Rearrangements. <i>Blood</i> , 2010, 116, 4835-4835.	1.4	0
35	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. <i>Blood</i> , 2010, 116, 4053-4053.	1.4	0
36	Staging and survival in multiple myeloma. <i>Scandinavian Journal of Haematology</i> , 2009, 33, 22-26.	0.0	11

#	ARTICLE	IF	CITATIONS
37	Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*. European Journal of Haematology, 2009, 41, 375-381.	2.2	146
38	Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. European Journal of Haematology, 2009, 83, 99-107.	2.2	35
39	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. International Journal of Cancer, 2009, 125, 2147-2150.	5.1	63
40	Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 2009, 113, 4179-4187.	1.4	811
41	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	1.4	133
42	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	3.5	95
43	Fludarabine, Cyclophosphamide and Rituximab (FCR) induced pulmonary hypertension in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2008, 49, 1209-1211.	1.3	7
44	Accumulating evidence for a role of p53 in multiple drug resistant Acute Myeloid Leukemia. Leukemia and Lymphoma, 2008, 49, 383-384.	1.3	1
45	Genital Graft-versus-host Disease in a Male Following Allogeneic Stem Cell Transplantation. Acta Dermato-Venereologica, 2007, 87, 367-368.	1.3	10
46	Hiccups and severe hyponatremia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation. American Journal of Hematology, 2007, 82, 88-88.	4.1	10
47	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 2007, 24, 63-70.	2.5	19
48	Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.. Blood, 2007, 110, 660-660.	1.4	0
49	Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leukemia and Lymphoma, 2006, 47, 1987-1988.	1.3	4
50	Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leukemia and Lymphoma, 2006, 47, 1768-1773.	1.3	5
51	Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia, 2006, 20, 42-47.	7.2	91
52	Chromosome aberrations including der(6)t(2;6)(p15;p21.3) and der(22)t(3;22)(p21;p11) in the evolution of essential thrombocythemia to myelofibrosis with myeloid metaplasia. Cancer Genetics and Cytogenetics, 2006, 165, 87-89.	1.0	1
53	Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML. American Journal of Hematology, 2006, 81, 470-471.	4.1	25
54	Measurement of iron and zinc isotopes in human whole blood: Preliminary application to the study of HFE genotypes. Journal of Trace Elements in Medicine and Biology, 2005, 19, 55-60.	3.0	45

#	ARTICLE	IF	CITATIONS
55	Bone Marrow Hyaluronan Distribution in Patients with Acute Myeloid Leukemia. <i>Medical Oncology</i> , 2005, 22, 071-078.	2.5	15
56	Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. <i>Bone Marrow Transplantation</i> , 2005, 35, 1141-1148.	2.4	20
57	Intensive Treatment and Stem Cell Transplantation in Chronic Myelogenous Leukemia: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2005, 113, 155-162.	1.4	20
58	Transplantation after reduced intensity conditioning in patients with acute myeloid leukaemia in Sweden. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 33.	2.0	0
59	Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. <i>The Hematology Journal</i> , 2004, 5, 462-466.	1.4	7
60	Haematopoietic stem cell transplantation for refractory autoimmune cytopenia. <i>British Journal of Haematology</i> , 2004, 125, 749-755.	2.5	73
61	Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. <i>European Journal of Haematology</i> , 2004, 73, 263-268.	2.2	12
62	Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. <i>European Journal of Haematology</i> , 2003, 70, 240-241.	2.2	15
63	Evidence for a bimodal relation between serum lysozyme and prognosis in 232 patients with acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2003, 70, 26-33.	2.2	7
64	No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. <i>Leukemia</i> , 2003, 17, 1827-1833.	7.2	32
65	Co-existence of pseudo-Chediak-Higashi anomaly and double minutes containing C-MYC oncogene in three patients with AML M2. <i>Leukemia</i> , 2002, 16, 152-154.	7.2	9
66	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. <i>European Journal of Haematology</i> , 2002, 68, 54-63.	2.2	16
67	High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 118, 748-754.	2.5	50
68	Adverse drug reactions as a cause for admissions to a department of internal medicine. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 65-72.	1.9	168
69	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001, 115, 25-33.	2.5	79
70	Glycoconjugate abnormalities in patients with congenital dyserythropoietic anaemia type I, II and III. <i>British Journal of Haematology</i> , 2001, 114, 907-913.	2.5	13
71	Geriatric-Based Versus General Wards for Older Acute Medical Patients: A Randomized Comparison of Outcomes and Use of Resources. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 1381-1388.	2.6	140
72	Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. <i>Carcinogenesis</i> , 1999, 20, 1231-1233.	2.8	79

#	ARTICLE	IF	CITATIONS
73	Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma. <i>Lancet, The</i> , 1998, 352, 1285-1286.	13.7	25
74	Intestinal permeability in patients with acute myeloid leukemia. <i>European Journal of Haematology</i> , 1998, 61, 250-254.	2.2	33
75	Comparison of Efficacies of Ondansetron and Dicyclanil for Prophylaxis of Emesis During Induction Treatment in Acute Myelogenous Leukemia: A Pilot Study. <i>Acta Oncologica</i> , 1997, 36, 229-230.	1.8	4
76	Angioid streaks are part of a familial syndrome of dyserythropoietic anaemia (CDA III). <i>British Journal of Haematology</i> , 1997, 98, 845-849.	2.5	34
77	Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for <i>de novo</i> acute myeloid leukemia. <i>European Journal of Haematology</i> , 1997, 58, 233-240.	2.2	7
78	Indications for and Referrals to Oral Care for Cancer Patients in a County Hospital. <i>Acta Oncologica</i> , 1996, 35, 743-748.	1.8	6
79	Localization of the gene for congenital dyserythropoietic anemia type III, CDAN3, to chromosome 15q21-q25. <i>Human Molecular Genetics</i> , 1995, 4, 109-112.	2.9	62
80	Myelodysplastic Syndromes—A Population-Based Study on Transformation and Survival. <i>Acta Oncologica</i> , 1995, 34, 473-478.	1.8	1
81	Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. <i>Annals of Oncology</i> , 1994, 5, S67-S71.	1.2	84
82	Serum thymidine kinase in congenital dyserythropoietic anaemia type III. <i>British Journal of Haematology</i> , 1994, 87, 653-654.	2.5	12
83	Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anaemia, type III. <i>European Journal of Haematology</i> , 1994, 52, 42-46.	2.2	42
84	Intensive treatment in order to minimize the ph&hyphen;positive clone in chronic myelogenous leukemia. <i>Stem Cells</i> , 1993, 11, 73-76.	3.2	21
85	Intensive Treatment in order to Minimize the Ph-Positive Clone in Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 55-57.	1.3	16
86	A Pilot Study of Piperacillin and Ciprofloxacin as Initial Therapy for Fever in Severely Neutropenic Leukemia Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1992, 24, 467-475.	1.5	8
87	Multiple DNA Rearrangements in the BCL2 Region in a Patient With Follicular Lymphoma. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 390-393.	2.8	1
88	Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 480-483.	2.3	20
89	Remission rate and survival in acute myeloid leukemia: Impact of selection and chemotherapy. <i>European Journal of Haematology</i> , 1991, 46, 240-247.	2.2	34
90	Factors Influencing the Efficacy of Platelet Transfusions in Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1990, 2, 341-346.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. <i>Cancer Genetics and Cytogenetics</i> , 1990, 49, 57-67.	1.0	64
92	Reversal of myelofibrosis by hydroxyurea. <i>European Journal of Haematology</i> , 1990, 44, 33-38.	2.2	89
93	Life table analysis for estimation of duration of aplasia after high-dose chemotherapy. <i>European Journal of Haematology</i> , 1990, 45, 284-285.	2.2	0
94	Philadelphia chromosome negative acute lymphoblastic leukemia preceding Philadelphia positive chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1989, 39, 147-152.	1.0	3
95	Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1989, 6, 199-205.	1.1	6
96	Effects of Plasmapheresis on the Plasma Concentration of Proteins Used to Monitor the Disease Process in Multiple Myeloma. <i>Acta Medica Scandinavica</i> , 1988, 223, 263-267.	0.0	1
97	Improved Survival in Multiple Myeloma with Renal Failure. <i>Acta Medica Scandinavica</i> , 1987, 221, 205-209.	0.0	28
98	Hydroxyurea Treatment of Myeloproliferative Disorders. <i>Acta Medica Scandinavica</i> , 1987, 222, 169-174.	0.0	11
99	Chronic monocytic leukemia terminating in blastic transformation. <i>Blut</i> , 1986, 53, 405-409.	1.2	0
100	THE SIGNIFICANCE OF HANDMIRROR CELLS IN ACUTE MYELOCYTIC LEUKAEMIA TYPE M1 AND M2 AFTER WEAK CYTOSTATIC TREATMENT. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology</i> , 1986, 94A, 149-152.	0.3	0
101	T-cell subsets in multiple myeloma. <i>Blut</i> , 1985, 51, 291-295.	1.2	4
102	Nonfamilial Polycystic Kidneys without Enlargement. <i>Nephron</i> , 1985, 39, 134-140.	1.8	6
103	Staging of Idiopathic Myelofibrosis: Significance of Haemoglobin Value and Reticulocyte Count. <i>Acta Medica Scandinavica</i> , 1985, 218, 487-491.	0.0	14
104	Long-Term Lithium Treatment and Renal Functions. <i>Neuropsychobiology</i> , 1984, 11, 33-38.	1.9	15
105	Lithium Therapy and Thyroid Function Tests. <i>Neuropsychobiology</i> , 1984, 11, 39-43.	1.9	48
106	ECG Changes during Lithium Therapy. <i>Acta Medica Scandinavica</i> , 1984, 216, 101-104.	0.0	21
107	Myeloma-Associated Cardiac Amyloidosis: A Case Report. <i>Acta Medica Scandinavica</i> , 1984, 215, 189-192.	0.0	2
108	Treatment of Advanced Bone Marrow Neoplasms with Ifosfamide Combinations. <i>Scandinavian Journal of Haematology</i> , 1984, 32, 95-100.	0.0	3

#	ARTICLE	IF	CITATIONS
109	Plasma Proteins and Anti-Kidney Antibodies in Renal Carcinoma. Scandinavian Journal of Urology and Nephrology, 1982, 16, 163-166.	1.4	4
110	Melphalanâ€Related Leukemia in Multiple Myeloma. Acta Medica Scandinavica, 1982, 211, 203-208.	0.0	13
111	Urine Microscopy as Screening Method for Bacteriuria. Acta Medica Scandinavica, 1982, 211, 209-211.	0.0	14
112	Renal Function in Familial Amyloidosis with Polyneuropathy. Acta Medica Scandinavica, 1982, 212, 233-236.	0.0	20
113	Evaluation of Serial Bone Xâ€ray Examination in Multiple Myeloma. Acta Medica Scandinavica, 1982, 212, 385-387.	0.0	28
114	Response to Busulphan Treatment of Paroxysmal Nocturnal Hemoglobinuria and Myelofibrosis in One and the Same Patient. Acta Medica Scandinavica, 1981, 209, 133-135.	0.0	5
115	Kidney Function in Patients with Affective Disorders with and without Lithium Therapy. International Pharmacopsychiatry, 1980, 15, 253-259.	0.4	24
116	Failure of Chlorothiazide to Improve Urinary Concentrating Capacity in Lithiumâ€treated Patients. Acta Medica Scandinavica, 1980, 207, 195-196.	0.0	5
117	Renal Concentrating Capacity in Longâ€Term Lithium Treatment and after Withdrawal of Lithium. Acta Medica Scandinavica, 1980, 207, 309-314.	0.0	78
118	Identification of Renal Tubular Epithelial Cells in Urine with Immunofluorescence. Acta Medica Scandinavica, 1979, 205, 587-591.	0.0	3
119	IMPAIRMENT OF RENAL CONCENTRATING CAPACITY BY LITHIUM. Lancet, The, 1978, 311, 778-779.	13.7	38
120	URINE MICROSCOPY. Lancet, The, 1978, 312, 1052.	13.7	1
121	Differential Count and Quantitative Estimation of Granulocytes, Mononuclear Leukocytes and Renal Epithelial Cells in Urine. Upsala Journal of Medical Sciences, 1978, 83, 109-114.	0.9	3
122	Differential Count of Urinary Leukocytes and Renal Epithelial Cells. Upsala Journal of Medical Sciences, 1977, 82, 43-47.	0.9	4
123	The Urinary Sediment in Hydronephrosis. Acta Medica Scandinavica, 1977, 201, 449-452.	0.0	4
124	The Urinary Sediment in Endemic Benign Nephropathy. Acta Medica Scandinavica, 1977, 202, 51-54.	0.0	6
125	Differential Count of Urinary Leucocytes and Renal Epithelial Cells by Phase Contrast Microscopy. Acta Medica Scandinavica, 1975, 198, 505-509.	0.0	9